13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00645749 (ClinicalTrials.gov) | July 2008 | 25/3/2008 | Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis | Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Biological: Helminth ova | University of Wisconsin, Madison | National Multiple Sclerosis Society | Completed | 18 Years | 50 Years | All | 17 | Phase 1 | United States |